Dyax Corp. (NASDAQ: DYAX) announced today the appointment of Todd Bazemore as Executive Vice President and Chief Commercial Officer. Mr. Bazemore will be responsible for leading Dyax’s commercial organization which currently markets KALBITOR ® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. Mr. Bazemore joins Dyax as a pharmaceutical executive with 20 years of leadership and commercial operating experience in sales, marketing and managed markets. He most recently served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc. (formerly Sepracor). Prior to this, he served as Vice President of Sales and Marketing leading the Sunovion Respiratory Business Unit where he was responsible for the overall strategic direction and financial performance of the unit which generated $680 million in annual revenue. During his time at Sunovion, Mr. Bazemore held several roles of increasing responsibility in marketing and sales leadership including Vice President of Sales for the Pinnacle Sales Team, which was responsible for promoting OMNARIS ®, as well as LUNESTA ®, one of the most successful pharmaceutical product launches in the U.S. He also went on to build and oversee multiple sales and marketing teams responsible for several successful new product launches including BROVANA ® and XOPENEX ®. “Todd is a senior healthcare executive with two decades of commercial experience in both primary care and specialty markets, which makes him ideally suited to lead our commercial team,” said Gustav Christensen, President and Chief Executive Officer of Dyax. “His strong track record of strategic leadership, operational execution, and launching and developing brands will be highly valuable as we aim to grow our KALBITOR business and as we develop plans for how to optimize the value of DX-2930 which is currently in clinical development.” Mr. Bazemore stated, “It's a privilege to join the Dyax team during this important time as we continue to successfully commercialize KALBITOR and develop our future plans for DX-2930. I'm excited about the opportunity we have to truly help both the patients suffering from HAE and the physicians that treat them.”
About DyaxDyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company currently markets KALBITOR ® for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. Dyax is also developing DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein, for the prophylactic treatment of HAE. Additionally, the Company has developed a biomarker assay that detects activated plasma kallikrein in blood and is being used for internal research and development efforts, including the exploration and identification of other plasma-kallikrein-mediated indications beyond HAE. Both KALBITOR and DX-2930 were identified using Dyax's patented phage display technology. Dyax has broadly licensed this technology and has a portfolio of product candidates being developed by our licensees, which it refers to as the Licensing and Funded Research Portfolio (LFRP). The Company is eligible to receive future milestones and/or royalties dependent upon the development and commercialization of these candidates. For additional information about Dyax, please visit www.dyax.com. For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com. Disclaimer This press release contains forward-looking statements. Statements that are not historical facts are based on Dyax's current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect future performance include the risks that: DX-2930 may not show sufficient therapeutic effect or an acceptable safety profile in clinical trials or could take longer to gain regulatory approval than Dyax expects or may never gain approval; others may develop products superior to KALBITOR or DX-2930; KALBITOR and/or DX-2930 may not gain market acceptance; Dyax is dependent on the expertise, effort, priorities and contractual obligations of third parties in the manufacture, marketing, sales and distribution of KALBITOR and DX-2930; and other risk factors described or referred to in Item 1A, "Risk Factors" in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered marks of Dyax Corp.